Los Angeles, USA , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020 

NASH Drug Pipeline Shows Promise as 95+ companies are working for Nonalcoholic Steatohepatitis Drug Development 

Nonalcoholic Steatohepatitis (NASH) Pipeline Insight, 2020” by DelveInsight highlights the details around the NASH pipeline scenario, unmet needs, and NonAlcoholic Steatohepatitis therapeutic assessment of the key pipeline therapies. 

Some of the key Nonalcoholic Steatohepatitis Pipeline Highlights

  • 95+ key companies are working to strengthen the Nonalcoholic Steatohepatitis pipeline including the AstraZeneca, Eli Lilly, Pfizer and several others.
  • Nonalcoholic Steatohepatitis market presents promising and a vast new product pipeline with pivotal trials, NME Projects and phase-advancing therapeutic candidates.
  • 90+ Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include: GB1211, AZD2693, Tropifexor (LJN452), etc.
  • Collaborations and Deals
  • Pipeline Drug Profiles provided include:
    • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
    • Phases of development
    • Mechanism of Action
    • Route of Administration
    • Companies involved including originator, licensing companies, developer, investors, and others
    • New molecular entity details
    • Drug designations and other special status provided by regulatory authorities
  • Market Drivers and Barriers

Nonalcoholic Steatohepatitis (NASH) is a form of fatty liver disease that can cause inflammation, and over the long term, can lead to scarring of the liver. Nonalcoholic Steatohepatitis symptoms include fatigue and pain in the upper right abdomen. There is no standard treatment for NASH patients, but lifestyle changes have influenced its progression. 

Get access to NASH Treatment Pipeline Sample Report 

NASH Pipeline Therapeutics

  • EYP001 by ENYO Pharma

ENYO Pharma develops EYP001, which is an orally bioavailable synthetic non-steroidal, non-bile acid FXR agonist small molecule that is also developed for NASH.  FXR agonists could become the backbone of any future NASH therapies. The pioneering ENYO founding team discovered that FXR agonists interfere with the interaction between FXR and HBx, a hepatitis B viral protein essential for replicating the virus. It has demonstrated its efficacy in a Stelic mouse model (STAMTM) with a significant positive impact on most of the NASH key parameters (Fibrosis, Steatosis, Inflammation, Ballooning, triglycerides, and NAS). It differentiates from other FXR agonists with a potentially better C4/FGF19 balance.

To learn more about NASH Drugs Development, request NASH Treatment Pipeline Sample Report 

Scope of Nonalcoholic Steatohepatitis Drug Pipeline Report 

  • Coverage: Global 
  • Major Players: 95+ Key Companies  
  • Prominent Players: 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Akero Therapeutics Inc, Albireo Pharma Inc, Aldeyra Therapeutics Inc, Ascletis Pharma Inc, Zhejiang Doer Biologics Corp, Asdera LLC, Assembly Biosciences Inc, AstraZeneca Plc, Auransa Inc, Avaliv Therapeutics Inc, Avolynt Inc, ChemoCentryx Inc, ChemomAb Ltd, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, DURECT Corp, Eli Lilly and Co, Enanta Pharmaceuticals Inc EncuraGen Inc, Engitix Ltd, Hepion Pharmaceuticals Inc, Heprotech Inc, Hinova Pharmaceuticals Inc, HK inno.N Corp, HotSpot Therapeutics Inc, Ildong Pharmaceutical Co Ltd, Imago Pharmaceuticals Inc, ImmuneMed Inc, Immupharma Plc, Immuron Ltd, Indalo Therapeutics Inc, Inmune Bio Inc, Innovimmune Biotherapeutics Inc, Inorbit Therapeutics AB, Integral Molecular Inc, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, InventisBio Inc, Inventiva, LG Chem Ltd, LifeMax Laboratories Inc, Metabolys SAS, Metacrine Inc, Pattern Therapeutics, PegBio Co Ltd, Pfizer Inc, RadBio, Redx Pharma Plc, Regenasome Pty Ltd, Regulus Therapeutics Inc, SparkBioPharma Inc, SteroTherapeutics LLC, T3D Therapeutics Inc, TaiwanJ Pharmaceuticals Co Ltd, Thoth Science Inc, Wave Life Sciences Ltd, Xenexus Pharmaceuticals Pty Ltd, Xfibra Inc, XORTX Therapeutics Inc, YD Life Science Co, Yuhan Corp Zebra Discovery Ltd, and many others.  
  • Key Drugs: 90+ Drugs
  • Nonalcoholic Steatohepatitis Pipeline TherapiesGB1211, AZD2693, Tropifexor (LJN452), ORMD-0801, (Insulin) capsule, ZSP1601, EYP001a, Miricorilant, MK-3655, BMS-986263, Tirzepatide, BFKB8488A, TERN-101, Namodenoson, Leronlimab, ORMD-0801 QD, PXL065, LPCN 1144 Formulation A, EFX, SNP-610, NGM282, Obeticholic acid (10 mg), LYS006, ALN-HSD, PF-06865571, Obeticholic Acid, SEL, and many others.
  • Phases:  
  • Nonalcoholic Steatohepatitis Therapies Late-stage (Phase III)  
  • NASH Therapies (Phase II)
  • Nonalcoholic Steatohepatitis Therapies (Phase I) 
  • NASH Therapies Pre-clinical stage candidates 
  • Inactive candidates and Discovery candidates 
  • Targets
  • Protease
  • Immune System 
  • Multiple Kinase 
  • Mechanism of Action
  • Protease Inhibitor 
  • Immunomodulatory 
  • Multiple Kinase Inhibitor
  • Molecule Types:  
  • Small molecule
  • Stem Cell Therapy 
  • Gene Therapy 
  • Route of Administration:
  • Inhalation
  • Intravenous
  • Oral
  • Subcutaneous
  • Product Types:
  • Mono
  • Combination 

Key Questions regarding Current NASH Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

  • What are the current options for Nonalcoholic Steatohepatitis treatment?
  • How many companies are developing therapies for the treatment of Nonalcoholic Steatohepatitis? 
  • How many NASH emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Nonalcoholic Steatohepatitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Nonalcoholic Steatohepatitis market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of NASH?  
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Nonalcoholic Steatohepatitis therapies? 
  • What are the key designations that have been granted for the emerging therapies for Nonalcoholic Steatohepatitis? 
  • How many patents are granted and pending for the emerging therapies for the treatment of NASH? 

Table of Contents 

2Executive Summary of NonAlcoholic Steatohepatitis
3NASH Overview
4NonAlcoholic Steatohepatitis Analytical Perspective In-depth Commercial Assessment
5NASH Pipeline Therapeutics
6NonAlcoholic Steatohepatitis Late Stage Products (Registered)
7NASH Late Stage Products (Phase III)
7.1Cenicriviroc: Tobira Therapeutics
8NonAlcoholic Steatohepatitis Mid Stage Products (Phase II)
8.1Tropifexor: Novartis
8.2EYP 001: ENYO Pharma
9NASH Early Stage Products (Phase I)
9.1ION 839: Ionis Pharmaceuticals / AstraZeneca
10NonAlcoholic Steatohepatitis Pre-clinical and Discovery Stage Products
10.1Nitazoxanide: Genfit 
11NASH Therapeutic Assessment
12NonAlcoholic Steatohepatitis Inactive Products
13Company-University Collaborations (Licensing/Partnering) Analysis
14NASH Key Companies
15NonAlcoholic Steatohepatitis Key Products
16NASH Unmet Needs
17NonAlcoholic Steatohepatitis Market Drivers and Barriers
18NASH- Future Perspectives and Conclusion
19NonAlcoholic Steatohepatitis Analyst Views

Browse Detailed TOC, Emerging Drugs and Key Companies @ NASH Pipeline Scenario 

Related Reports 

DelveInsight's Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

DelveInsight's Nonalcoholic Steatohepatitis (NASH) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Nonalcoholic Steatohepatitis (NASH) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

DelveInsight' s Non Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

DelveInsight's Non Alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Non Alcoholic Fatty Liver Disease (NAFLD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Non Alcoholic Fatty Liver Disease (NAFLD) Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Non Alcoholic Fatty Liver Disease (NAFLD).

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Non Alcoholic Fatty Liver Disease (NAFLD) market.

DelveInsight's Hepatitis C Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  

Contact Us:

Shruti Thakur